Theravance Biopharma ( (TBPH) ) has released its Q1 earnings. Here is a breakdown of the information Theravance Biopharma presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing respiratory and neurological therapies, with a notable product being YUPELRI for COPD treatment.
In its first quarter of 2025, Theravance Biopharma reported a 6% increase in YUPELRI net sales, reaching $58.3 million, and a 14% increase in TRELEGY net sales, as reported by GSK. The company also highlighted nearing completion of the CYPRESS study enrollment for ampreloxetine, aimed at treating symptomatic neurogenic orthostatic hypotension in multiple system atrophy patients.
Key financial metrics included a total revenue of $15.4 million, driven by Viatris collaboration revenue, and a net loss of $13.6 million. The company maintained a strong cash position with $131 million and reaffirmed its financial guidance for 2025. Additionally, research and development expenses rose to $11.5 million, reflecting ongoing investment in clinical advancements.
Theravance Biopharma’s strategic focus remains on advancing its pipeline, particularly the CYPRESS study, and maximizing the commercial potential of its existing products. The company continues to explore strategic alternatives to enhance shareholder value.
Looking ahead, Theravance Biopharma is committed to achieving its operational priorities and advancing its clinical programs, with a focus on delivering long-term value through its innovative therapies.